<DOC>
	<DOC>NCT00595413</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to methotrexate (MTX) and no previous exposure to anti-tumor necrosis factor alpha (anti-TNFalpha) therapy.</brief_summary>
	<brief_title>Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male or female subjects greater than or equal to (&gt;=) 18 years of age at the time of informed consent who have RA satisfying American College of Rheumatology (ACR) criteria with a disease history of at least 6 months Subjects must have active disease, defined by &gt;=8 swollen joints (out of 66), &gt;=8 tender joints (out of 68) and CRP &gt;=10 milligram per liter (mg/L) and/or erythrocyte sedimentation rate (ESR) &gt;=28 millimeter per hour (mm/hr), despite treatment with MTX at a dose of &gt;=15 milligram per week (mg/week) for greater than (&gt;) 3 months Other protocoldefined inclusion criteria could apply Inflammatory joint disease other than RA Previous or concurrent treatment with any approved or investigational biological compound for RA, including but not restricted to any antiTNFalpha agents, rituximab, abatacept, tocilizumab, interleukin1 receptor antagonist (IL1Ra) and belimumab Treatment with diseasemodifying antirheumatic drug (DMARDs) other than MTX Participation in any interventional clinical trial within 1 month before study Day 1 MTX dose &gt;25 mg/week, prednisone dose &gt;10 mg/day (or equivalent), or change in steroid or nonsteroidal antiinflammatory drug (NSAID) dosing regimen within 28 days before study Day 1 Immunization with live vaccine or immunoglobulin (Ig) treatment within 28 days before study Day 1 or need for such treatment during the study (including followup) Any history or presence of active or latent tuberculosis, major infection requiring hospitalization or intravenous antiinfectives within 28 days before study Day 1 Other major concurrent illness or organ dysfunction as specified in the protocol Serum IgG below 6 gram per liter (g/L) Known hypersensitivity to atacicept or to any of the components of the formulated atacicept Other protocoldefined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Atacicept</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Humira®</keyword>
</DOC>